Levodopa and 3-O-methyldopa in cerebrospinal fluid after levodopa-carbidopa association

Pharmacological Research

Volumn 35, Issue 4, 1997, Pages 313-315

  Benetello, P ^a   Furlanut, M ^b   Fortunato, M ^b   Pea, F ^b   Baraldo, M ^b  

^a Institute of Neurology   (Italy)

^b NONE

Author keywords

3 O methyldopa; Cerebrospinal fluid; Levodopa

Indexed keywords

CARBIDOPA; CARBIDOPA PLUS LEVODOPA; LEVODOPA;

ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; FEMALE; HUMAN; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0031126766     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1997.0145     Document Type: Article

References (18)

1. Fahn S. On-off phenomenon with levodopa therapy in parkinsonism. Neurology. 24:1974;431-441.
2. Marsden CD, Parkes JD. On-off effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet. 1:1976;292-296.
3. Yahr MD. Long-term levodopa in Parkinson's disease. Lancet. 1:1977;706-707.
4. Lee T, Seeman P, Rajput A, Farley IJ, Hornykiewicz O. Receptor basis for dopaminergic supersensitivity in Parkinson's disease. Nature. 273:1978;59-61.
5. Post RM. Intermittent versus continuous stimulation: effect of time interval on the development of sensitization or tolerance. Life Sci. 26:1980;1275-1282.
6. Spencer SE, Wooten GF. Altered pharmacokinetics of L-dopa metabolism in rat striatum deprived of dopaminergic innervation. Neurology. 34:1984;1105-1108.
7. Fabbrini G, Mouradian MM, Juncos JL, Schlegel J, Mohn E, Chase TN. Motor fluctuations in Parkinson's disease, I: central pathophysiological mechanism. Ann Neurol. 24:1988;336-371.
8. Mouradian MM, Juncos JL, Fabbrini G, Schlegel J, Mohn E, Chase TN. Motor fluctuations in Parkinson's disease, II: central pathophysiological mechanism. Ann Neurol. 24:1988;372-378.
9. Nutt JG, Gancher ST, Woodward WR. Does an inhibitory action ofL. Neurology. 38:1988;1553-1557.
10. Wade LA, Katzman R. 3-O-methyldopa uptake and inhibition ofL. Life Sci. 17:1975;131-136.
11. Gervas JJ, Muradas V, Bazan E, Aguado EG, de Yebenes JG. Effects of 3-OMD on monoamine metabolism in rat brain. Neurology. 33:1983;278-282.
12. Nutt JG, Woodward WR, Gancher ST, Merrick D. 3-OMD and the response of levodopa in Parkinson's disease. Ann Neurol. 21:1987;584-588.
13. Fabbrini G, Juncos JL, Mouradian MM, Serrati C, Chase TN. 3-OMD and motor fluctuations in Parkinson's disease. Neurology. 37:1987;856-859.
14. Cedarbaum JM, Kutt H, McDowell FH. Clinical significance of the relationship between 3-OMD levels and levodopa intake. Neurology. 38:1988;533-536.
15. Benetello P, Furlanut M, Zara G, Baraldo M, Eid H. Plasma levels of levodopa and its main metabolites in parkinsonian patients after conventional and controlled-release levodopa-carbidopa associations. Eur Neurol. 33:1993;69-73.
16. Nissinen E, Taskinen J. Simultaneous determination of carbidopa, levodopa and 3,4-dihydroxyphenylacetic acid using high-performance liquid chromatography with electrochemical detection. J Chromatogr. 231:1982;459-462.
17. Mena MA, Muradas D, Bazan E, Reiriz J, de Yebenes JG. Pharmacokinetics ofL. Adv Neurol. 45:1986;481-486.
18. Hammerstad JP, Woodward WR, Gliessman P, Boucher B, Nutt JG. L. Ann Neurol. 27:1990;495-499.